Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 201335 with pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 1
2008-003538-11Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2008
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of faldaprevir in hepatitis C virus infection (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Co-primary efficacy endpoint 1 and Co-primary efficacy endpoint 2. Started Jul 2008; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2008-003538-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003538-11.